

17. (Amended) The antibody of Claim 16, wherein said antibody is directed against an AAV capsid or a protein thereof.

18. (Amended) The antibody of Claim 17, wherein said antibody is A1 as deposited with DSM under deposit number ACC2195.

19. (Amended) The antibody of Claim 17, wherein said antibody is A20 as deposited with DSM under deposit number ACC2194.

20. (Amended) The antibody of Claim 17, wherein said antibody is A69 as deposited with DSM under deposit number ACC2196.

21. (Amended) The antibody of Claim 17, wherein said antibody is B1 as deposited with DSM under deposit number ACC2197.

---

#### REMARKS

Claims 1-11, 14, and 15 have been canceled as belonging to a non-elected invention. Claims 12, 13, and 16-21 are pending.

**The Amendments.** The claims have been amended to avoid dependencies from non-elected claims. The amendments do not introduce new matter, and they are fully supported in the specification and the claims as originally filed. Entry pursuant to 37 C.F.R. § 1.111 is therefore respectfully requested. A marked-up copy of the amended claims is attached hereto as *Appendix A*. The claims as presently pending are attached hereto as *Appendix B*.

**Response to Restriction Requirement.** In response to the requirement for restriction, Applicants hereby elect Group II, encompassing Claims 12, 13, 16-21, which are drawn to anti-AAV antibody products, without traverse. Applicants reserve the right to pursue Group I, encompassing Claims 1-11, and Group III, encompassing Claims 14-15, in later filed divisional applications.